Nokwanda E Bam1, Sikhumbuzo A Mabunda2, Jafta Ntsaba1, Teke Apalata3, Sibusiso C Nomatshila4, Wezile Chitha5. 1. Department of Nursing, Walter Sisulu University, Mthatha, South Africa. 2. The George Institute for Global Health, University of New South Wales, Sydney, Australia. 3. Department of Laboratory Medicine, Walter Sisulu University, Mthatha, South Africa. 4. Department of Public Health, Walter Sisulu University, Mthatha, South Africa. 5. Health Systems Enablement & Innovation Unit, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
BACKGROUND: Combination antiretroviral drugs (cARVs) prolong patients' lives but are unfortunately thought to increase complications related to metabolic disorders including type-2 Diabetes Mellitus (DM). We sought to confirm the association of cARVs with type-2 DM and ascertain the extent of this association in a rural South African setting. METHODS: A case-control study of 177 (33.33%) cases with HIV/AIDS and type-2 DM were selected and compared with 354 (66.67%) non-DM HIV/AIDS unmatched controls from a rural district of South Africa's third most populous province (Eastern Cape). Cases were identified from community health centres using the district health information system, and controls were identified using simple random sampling from the same health facilities. Odds Ratios (OR), together with 95% confidence intervals, were calculated for all the univariable and multivariable logistic analyses. RESULTS: This study found that cARVs significantly increased the occurrence of type-2 DM among HIV patients. Patients on protease inhibitors (PIs) were at least 21 times significantly (p<0.0001) more likely to be diabetic than those on the fixed dose combination (FDC); those on stavudine (D4T) and zidovudine (AZT) were 2.45 times and 9.44 times respectively more likely to be diabetic than those on FDC (p<0.05). The odds of diabetes increased by more than three-folds for those who had been on antiretroviral drugs for more than 6 years (p<0.005). CONCLUSION: This study has been able to establish the association between cARVs and type-2 DM. It therefore proposes consideration of the usage of AZT, D4T, lopivavir and ritonavir for the treatment of HIV. The study further proposes more prospective research to test these findings further.
BACKGROUND: Combination antiretroviral drugs (cARVs) prolong patients' lives but are unfortunately thought to increase complications related to metabolic disorders including type-2 Diabetes Mellitus (DM). We sought to confirm the association of cARVs with type-2 DM and ascertain the extent of this association in a rural South African setting. METHODS: A case-control study of 177 (33.33%) cases with HIV/AIDS and type-2 DM were selected and compared with 354 (66.67%) non-DMHIV/AIDS unmatched controls from a rural district of South Africa's third most populous province (Eastern Cape). Cases were identified from community health centres using the district health information system, and controls were identified using simple random sampling from the same health facilities. Odds Ratios (OR), together with 95% confidence intervals, were calculated for all the univariable and multivariable logistic analyses. RESULTS: This study found that cARVs significantly increased the occurrence of type-2 DM among HIV patients. Patients on protease inhibitors (PIs) were at least 21 times significantly (p<0.0001) more likely to be diabetic than those on the fixed dose combination (FDC); those on stavudine (D4T) and zidovudine (AZT) were 2.45 times and 9.44 times respectively more likely to be diabetic than those on FDC (p<0.05). The odds of diabetes increased by more than three-folds for those who had been on antiretroviral drugs for more than 6 years (p<0.005). CONCLUSION: This study has been able to establish the association between cARVs and type-2 DM. It therefore proposes consideration of the usage of AZT, D4T, lopivavir and ritonavir for the treatment of HIV. The study further proposes more prospective research to test these findings further.
Authors: Jose Echecopar-Sabogal; Lorenzo D'Angelo-Piaggio; Diego M Chanamé-Baca; Cesar Ugarte-Gil Journal: Int J STD AIDS Date: 2017-09-28 Impact factor: 1.359
Authors: L G Ekali; L K Johnstone; J B Echouffo-Tcheugui; C Kouanfack; M Y Dehayem; L Fezeu; B Nouthe; L Hayes; N C Unwin; E Sobngwi Journal: Diabetes Metab Date: 2012-11-13 Impact factor: 6.041
Authors: Eugene Mutimura; Donald R Hoover; Qiuhu Shi; Jean Claude Dusingize; Jean D'Amour Sinayobye; Mardge Cohen; Kathryn Anastos Journal: PLoS One Date: 2015-04-16 Impact factor: 3.240
Authors: Alfonso C Hernandez-Romieu; Shikha Garg; Eli S Rosenberg; Angela M Thompson-Paul; Jacek Skarbinski Journal: BMJ Open Diabetes Res Care Date: 2017-01-05
Authors: Sekai C Mathabire Rücker; Alia Tayea; Joseph Bitilinyu-Bangoh; Elkin H Bermúdez-Aza; Leon Salumu; Isabel Amoros Quiles; Elisabeth Szumilin; Zengani Chirwa; Fernanda Rick; David Maman Journal: AIDS Date: 2018-01-14 Impact factor: 4.177
Authors: Kathy Petoumenos; Signe W Worm; Eric Fontas; Rainer Weber; Stephane De Wit; Mathias Bruyand; Peter Reiss; Wafaa El-Sadr; Antonella D'Arminio Monforte; Nina Friis-Møller; Jens D Lundgren; Matthew G Law Journal: J Int AIDS Soc Date: 2012-10-10 Impact factor: 5.396
Authors: Christian Akem Dimala; Julius Atashili; Josephine C Mbuagbaw; Akam Wilfred; Gottlieb L Monekosso Journal: PLoS One Date: 2016-05-19 Impact factor: 3.240
Authors: Nokwanda E Bam; Wezile Chitha; Jafta Ntsaba; Sibusiso C Nomatshila; Teke Apalata; Sikhumbuzo A Mabunda Journal: Afr J Prim Health Care Fam Med Date: 2022-05-12